Department of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Department of Neurosurgery, University of Texas, MD Anderson Cancer Center, Houston, Texas.
Pract Radiat Oncol. 2019 Mar;9(2):e142-e148. doi: 10.1016/j.prro.2018.10.008. Epub 2018 Oct 29.
Spine stereotactic radiosurgery delivers an ablative dose of radiation therapy (RT) with high conformity relative to standard fractionated RT. This technique is suboptimal for extended targets (>3 vertebral levels) owing to treatment alignment concerns or for patients with marked epidural extension. In these patients, we hypothesized that use of hypofractionated intensity modulated RT/volumetric modulated arc therapy to dose escalate the gross tumor volume (GTV) to 40 Gy as a spinal simultaneous integrated boost (SSIB) would allow for durable local control and palliation.
We retrospectively analyzed 15 separate spinal sites (12 patients) that were treated with the SSIB technique between 2012 and 2016. The GTV and clinical target volume were prescribed at 40 Gy and 30 Gy, respectively, in 10 fractions. The spinal cord was allowed a maximum point dose of 34 Gy. The GTV was defined as gross tumor. The clinical target volume encompassed the GTV in addition to the involved vertebral bodies, at-risk paraspinal space, and spinal canal, followed by a planning target volume expansion of 3 to 5 mm.
The median follow-up for patients in our cohort was 17 months. At 1 year, local control was 93%, and overall survival was 58%, with a median time to death after treatment of 7 months. No grade ≥2 neurologic toxicities were reported for any of the patients. Nine of 12 patients had pain at presentation, of which 7 patients (78%) reported improvement and/or complete resolution of their pain after treatment.
Our early experience using a dose of 40 Gy to the GTV delivered via an SSIB technique, in lieu of spine stereotactic radiation surgery but more aggressive than conventional palliative doses, provides durable local control and pain relief. This technique may allow for improved local control and palliation in patients with radioresistant disease compared with conventional 3-dimensional conformal fractionated RT.
脊柱立体定向放射外科(SRS)提供了一种高适形性的消融剂量放疗(RT),与标准分割 RT 相比。由于治疗对准问题或对于明显硬膜外延伸的患者,该技术对于扩展靶区(>3 个椎体水平)并不理想。在这些患者中,我们假设使用低分割调强放疗/容积旋转调强放疗来将大体肿瘤体积(GTV)剂量递增至 40 Gy 作为脊柱同步整合推量(SSIB),将允许持久的局部控制和缓解。
我们回顾性分析了 2012 年至 2016 年间采用 SSIB 技术治疗的 15 个不同的脊柱部位(12 例患者)。GTV 和临床靶区分别规定为 40 Gy 和 30 Gy,共 10 个分次。脊髓允许最大点剂量为 34 Gy。GTV 定义为大体肿瘤。临床靶区包括 GTV 以及受累的椎体、危险的椎旁间隙和椎管,随后进行 3 至 5 mm 的计划靶区扩展。
本队列患者的中位随访时间为 17 个月。1 年时,局部控制率为 93%,总生存率为 58%,治疗后中位死亡时间为 7 个月。没有患者出现任何≥2 级的神经毒性。12 例患者中有 9 例在就诊时有疼痛,其中 7 例(78%)患者在治疗后疼痛得到改善和/或完全缓解。
我们使用 40 Gy 的剂量,通过 SSIB 技术治疗 GTV,替代 SRS,但比常规姑息剂量更具侵袭性,提供了持久的局部控制和疼痛缓解。与常规三维适形分割 RT 相比,该技术可能在具有放射性耐药性疾病的患者中提供更好的局部控制和缓解。